Home / Business and Economy / GSK Sees Profits Soar, But Future Growth May Slow
GSK Sees Profits Soar, But Future Growth May Slow
4 Feb
Summary
- GSK reported a 4% turnover increase to £32.7 billion in 2025.
- Specialty medicines, including HIV and asthma treatments, drove sales growth.
- The company anticipates a moderation in profit growth for 2026.
Pharmaceutical leader GSK has reported a substantial profit increase for 2025, with turnover climbing by 4% to £32.7 billion. This success was primarily fueled by strong demand for specialty medicines, including significant growth in respiratory, immunology, and inflammation treatments, alongside an 11% sales increase for HIV medication.
Under the leadership of new chief executive Luke Miels, GSK experienced robust trading. The company's core operating profits rose by 7% over the past year, accelerating to a 14% increase in the final quarter. Miels expressed confidence in GSK's position for future growth.
However, GSK has projected a moderation in its profit growth for 2026, expecting core operating profit growth between 7% and 9%. The company is also strategically avoiding the weight-loss drug market, preferring to focus on the downstream effects of obesity.
